What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Antibiotics/Anti-infectives

STEZOLID D/S

Linezolid 100mg Oral Suspension

Pack: 30ML
Format: With Carton

MRP₹139.69

A high-potency oxazolidinone antibacterial suspension designed for the intensive management of serious, multi-drug resistant Gram-positive pediatric infections. STEZOLID contains Linezolid 100mg, a critical-care antibiotic used to treat tough infections that have failed to respond to standard therapy.

About The Product

Key Benefits

Advanced Protein Synthesis Inhibition

Linezolid 100mg belongs to a unique class of oxazolidinone antibiotics. It works by preventing the initiation of bacterial protein synthesis at the ribosomal level. Because it attacks the bacteria at an earlier stage than most other antibiotics, it is highly effective against strains that have developed resistance to other drug classes.

Gold-Standard Treatment for Resistant Pathogens

STEZOLID is a frontline clinical choice for treating infections caused by resistant Gram-positive bacteria, including Methicillin-Resistant Staphylococcus Aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE). It provides a vital therapeutic option for pediatric cases where traditional penicillins or cephalosporins are no longer effective.

Intensive Respiratory and Skin Coverage

STEZOLID is highly indicated for community-acquired and nosocomial pneumonia, as well as complicated skin and soft tissue infections. Its excellent tissue penetration ensures that the antibiotic reaches deep-seated infection sites in the lungs and skin to rapidly eliminate harmful bacteria.

Superior Oral Bioavailability

One of the key advantages of Linezolid is its nearly 100% oral bioavailability. This means that STEZOLID Oral Suspension is just as effective as intravenous administration, allowing children to transition from hospital-based IV therapy to home-based oral treatment without losing any antibacterial potency.

Management of Complicated Infections

STEZOLID is engineered to address the most challenging pediatric infections, including those that are deep-seated or recurring. By providing a robust defense against multi-drug resistant organisms, it helps prevent the progression of severe illness and reduces the overall duration of hospital stays.

Precision Pediatric Formulation

The 100mg/5ml suspension format is specifically designed for pediatric patients who require intensive antibiotic therapy but cannot swallow tablets. This allows for accurate, weight-based dosing to ensure the child receives the exact therapeutic levels needed to combat serious infections while maintaining an excellent safety profile.

Indication Community-Acquired and Nosocomial Pneumonia, Complicated Skin and Soft Tissue Infections, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, Vancomycin-Resistant Enterococcus (VRE) Infections, Resistant Streptococcal Infections.

Indications

Community-Acquired and Nosocomial Pneumonia
Complicated Skin and Soft Tissue Infections
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Vancomycin-Resistant Enterococcus (VRE) Infections
Resistant Streptococcal Infections.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

STEZOLID D/S